Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. UCB
  6. Summary
    UCB   BE0003739530

UCB

(UCB)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
07/27/2021 07/28/2021 07/29/2021 07/30/2021 08/02/2021 Date
89.8(c) 90.32(c) 91.6(c) 91.2(c) 91.88 Last
199 911 224 500 408 738 331 144 194 136 Volume
+0.76% +0.58% +1.42% -0.44% +0.75% Change
More quotes
Estimated financial data (e)
Sales 2021 5 561 M 6 602 M 6 602 M
Net income 2021 906 M 1 076 M 1 076 M
Net Debt 2021 817 M 970 M 970 M
P/E ratio 2021 18,8x
Yield 2021 1,42%
Sales 2022 5 269 M 6 254 M 6 254 M
Net income 2022 830 M 986 M 986 M
Net Debt 2022 131 M 156 M 156 M
P/E ratio 2022 20,7x
Yield 2022 1,47%
Capitalization 17 348 M 20 618 M 20 595 M
EV / Sales 2021 3,27x
EV / Sales 2022 3,32x
Nbr of Employees 7 600
Free-Float 59,2%
More Financials
Company
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and ParkinsonÔÇÖs disease, and the area of immunology includes, bone... 
Sector
Pharmaceuticals
Calendar
09/08Presentation
More about the company
Ratings of UCB
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about UCB
02:12pUCB : Disposals of own shares
PU
07/29Ucb Sa Reports Earnings Results for the Half Year Ended June 30, 2021
CI
07/29UCB HY2021 FINANCIAL RESULTS : Solid performance despite the pandemic – de..
PU
07/29UCB : First half 2021 with sustainable performance – delivering on UCB's &..
PU
07/23UCB : Disposals of own shares
PU
07/16UCB : Disposals of own shares
PU
07/09UCB : Disposals of own shares
PU
07/09ANALYST RECOMMENDATIONS : Baidu, Canopy Growth, General Motors, Laredo Petroleum..
07/08UCB : With more than 90 years of innovation behind us, we …
PU
07/05UCB : is proud to partner on a new EU Research …
PU
06/30UNDERSTANDING THE IMPACT OF CHRONIC : update …
PU
06/28UCB : How AI is accelerating the development of new treatments for …
PU
06/25UCB : Disposals of own shares
PU
06/25UCB : Receives Positive CHMP Opinion Recommending Approval of BIMZELX (bimekizum..
PU
06/18UCB : Disposals of own shares
PU
More news
News in other languages on UCB
07/29BRUSSELS STOCK EXCHANGE : Brussel rood in zee van groen
07/29AB InBev en Telenet drukken koers Bel20
07/29AB InBev drukt Brussel in het rood
07/29AB InBev zet Brussel in het rood
07/29BRUSSELS STOCK EXCHANGE : Bel20 vermoedelijk neutraal van start op drukste cijfe..
More news
Analyst Recommendations on UCB
More recommendations
Chart UCB
Duration : Period :
UCB Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends UCB
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 91,88 €
Average target price 107,22 €
Spread / Average Target 16,7%
EPS Revisions
Managers and Directors
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Sandrine Dufour Chief Financial Officer & Executive Vice President
Stefan Oschmann Chairman
Iris L÷w-Friedrich Chief Medical Officer & EVP-Development
Dhavalkumar Patel Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
UCB7.95%20 427
CSL LIMITED3.94%96 600
WUXI BIOLOGICS (CAYMAN) INC.17.80%64 616
SAMSUNG BIOLOGICS CO.,LTD.10.53%51 119
BIOGEN INC.33.44%48 694
ALEXION PHARMACEUTICALS, INC.0.00%40 336